Real-world 10-year retrospective study of the guidelines for diagnosis and treatment of primary liver cancer in China

Table 1 Baseline characteristics of patients with different China Liver Cancer staging levels, n (%)

Variables	CNLC staging
	Total	Ia	Ιb	IIa	IIb	IIIa	IIIb	IV
Sex
Male	2487 (82.3)	492 (79.3)	365 (81.7)	47 (78.3)	742 (83.7)	468 (84.7)	295 (81.4)	78 (82.9)
Female	535 (17.7)	128 (20.7)	82 (18.3)	13 (21.7)	145 (16.3)	84 (16.3)	67 (18.6)	16 (17.1)
Age
≤ 50	884 (29.2)	185 (29.8)	116 (25.9)	16 (26.7)	245 (27.7)	175 (31.7)	112 (30.9)	35 (37.3)
> 50	2138 (70.8)	435 (70.2)	331 (74.1)	44 (73.3)	642 (72.3)	377 (68.3)	250 (69.1)	59 (62.7)
Chronic hepatitis
HBV	2793 (90.6)	558 (90.0)	398 (89.0)	52 (86.6)	808 (91.0)	513 (92.9)	323 (89.2)	87 (92.5)
HCV	187 (6.1)	48 (7.7)	22 (4.9)	6 (10.0)	54 (6.0)	32 (5.7)	19 (5.2)	6 (6.3)
NAFLD	106 (3.5)	34 (32.0)	27 (25.4)	0 (0.0)	23 (21.6)	12 (11.3)	8 (7.5)	2 (1.8)
ALD	24 (0.7)	4 (16.6)	3 (12.5)	1 (4.1)	7 (29.1)	6 (25.0)	2 (8.3)	1 (4.1)
Complications
Hypertension	533 (17.6)	125 (20.1)	87 (19.4)	9 (15.0)	158 (17.8)	82 (14.8)	60 (16.5)	12 (12.7)
Diabetes	360 (11.9)	75 (12.0)	42 (9.3)	12 (20.0)	112 (12.6)	68 (12.3)	39 (10.7)	12 (12.7)
Coronary heart disease	95 (3.1)	22 (3.5)	15 (3.3)	1 (1.6)	30 (3.3)	13 (2.3)	12 (3.3)	2 (2.1)
Smoking history	1158 (38.32)	215 (34.96)	170 (39.63)	25 (35.71)	340 (38.16)	223 (39.89)	152 (41.76)	33 (35.11)
Drinking history	949 (31.40)	182 (29.59)	136 (31.70)	18 (25.71)	277 (31.09)	176 (31.48)	128 (35.16)	32 (34.04)
AFP (ng/mL)
≤ 20	1094 (36.2)	345 (55.7)	187 (41.8)	42 (70.0)	318 (35.9)	115 (20.8)	90 (24.8)	16 (17.0)
20–400	757 (25.1)	170 (27.4)	101 (22.6)	18 (30.0)	223 (26.2)	132 (23.9)	80 (22.1)	22 (23.5)
> 400	1171 (38.7)	105 (16.9)	159 (35.6)	0 (0.0)	336 (37.9)	305 (55.2)	192 (53.1)	56 (59.5)

HBV: Hepatitis B virus; HCV: Hepatitis C virus; CNLC: China Liver Cancer staging; AFP: Alpha-fetoprotein; NAFLD: Non-alcoholic fatty liver disease; ALD: Alcoholic liver disease.